Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Restless Legs Syndrome
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how…
Ashok Battacharya, executive director of the Indian affiliate of Takeda Pharmaceuticals, with 38 years experience…
Think global, act local! This is the Novartis business approach in India. A great believer in stakeholder…
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio,…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its…